May 11, 2023
Takeda Presents Real-World Clinical Effectiveness and Safety Results of Vedolizumab (ENTYVIO®) and Ustekinumab as First-Line Biologic Treatment for Crohn’s Disease
March 30, 2023
Takeda Announces Results from Phase 4 Vedolizumab Study in Patients with Chronic Pouchitis Published in New England Journal of Medicine
December 1, 2022
LIVTENCITY™ (maribavir) Receives Positive CADTH Recommendation for Adults with Post-Transplant Cytomegalovirus (CMV) Infection
No current content.
Connect with us LinkedIn